Request Demo

Last update 21 Oct 2026

Inositol Nicotinate

Last update 21 Oct 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

hexanicotol, Inositol, Inositol hexanicotinate

+ [25]

Target

HCAR3 x NIACR1

Action

agonists

Mechanism

HCAR3 agonists(HM74 nicotinic acid GPCR agonists), NIACR1 agonists(Hydroxycarboxylic acid receptor 2 agonists)

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic Disease

Active Indication

HyperlipidemiasPeripheral Vascular Diseases

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC42H30N6O12

InChIKeyMFZCIDXOLLEMOO-GYSGTQPESA-N

CAS Registry6556-11-2

100 Clinical Results associated with Inositol Nicotinate

100 Translational Medicine associated with Inositol Nicotinate

100 Patents (Medical) associated with Inositol Nicotinate

Literatures (Medical) associated with Inositol Nicotinate

31 Dec 2024·JOURNAL OF DERMATOLOGICAL TREATMENT

Association between genetically proxied PPARG activation and psoriasis vulgaris: a Mendelian randomization study

Article

Author: Xue, Yan ; Xia, Yuning ; Mei, Ping ; Shi, Taiyu ; Hong, Sheng ; Cheng, Donghao

BACKGROUND:

Psoriasis is a common autoimmune disease in clinical practice, and previous observational studies have suggested that PPARG agonists such as Pioglitazone may be potential therapeutic agents. However, due to interference from various confounding factors, different observational studies have not reached a unified conclusion. We aim to evaluate the potential use of PPARG agonists for treating psoriasis from a new perspective through drug-targeted Mendelian randomization (MR) analysis.

MATERIALS AND METHODS:

This study includes data on 8,876 individuals for acute myocardial infarction from GWAS, and LDL cholesterol data from 343,621 Europeans. FinnGen contributed psoriasis vulgaris data for 403,972 individuals. The DrugBank10 databases function to identify genes encoding protein products targeted by active constituents of lipid-modifying targets. A two-sample MR analysis and summary-data-based MR (SMR) analysis estimated the associations between expressions of drug target genes and symptoms of psoriasis vulgaris. A multivariable MR study was further conducted to examine if the observed association was direct association.

RESULTS:

SMR analysis revealed that enhanced PPARG gene expression in the blood (equivalent to a one standard deviation increase) was a protective factor for psoriasis vulgaris (beta = -0.2017, se = 0.0723, p = 0.0053). Besides, there exists an MR association between LDL mediated by PPARG and psoriasis vulgaris outcomes (beta = -3.9169, se = 0.5676, p = 5.17E-12). These results indicate that PPARG is a therapeutic target for psoriasis, suggesting that psoriasis may be a potential indication for PPARG agonists.

CONCLUSION:

This study confirms that therapeutic activation of PPARG helps suppress the development of psoriasis. Psoriasis may be a new indication for PPARG agonists, such as Pioglitazone. In the future, new anti-psoriatic drugs could be developed targeting PPARG.

01 May 2023·Journal of Functional Foods

Red yeast rice preparations for dyslipidemia: An overview of systematic reviews and network meta-analysis

Author: Xue Xue ; Xuehan Liu ; Keji Chen ; Yaxin Guo ; Jianping Liu ; Chunli Lu ; Lijie Lu ; Fangfang Zhao ; Xinyan Jin ; Yuerong Jiang ; Luying Chen

This research was to summarize the comparative efficacy and safety of red yeast rice (RYR) preparations and analyze the treatment ranking of lipid-lowering agents including RYR.Thirty-one systematic reviews (SRs) involving 165 randomized trials with 14,987 dyslipidemia participants were included.All the SRs showed a high overall risk of bias.A Bayesian network meta-anal. was performed.Only five trials reported major adverse cardiovascular events (MACE) and three trials reported lipoprotein(a)[Lp(a)].Compared to placebo or other lipid-lowering drugs, RYR preparations showed some regulating action on lipids and glucose metabolism, with fewer side effects (P < 0.05).Compared to placebo, RYR showed a tendency to reduce Lp(a) levels.Lipid-lowering agents ranked differently in each outcome.High-quality evidence showed RYR (Zhibituo) lowered total cholesterol and triglyceride levels more than placebo.This study reveals the efficacy and safety ranking of RYR preparations for dyslipidemia, and its recommended that future trials should focus on MACE and Lp(a).

01 Jun 2021·International journal of pharmaceuticsQ2 · MEDICINE

Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease

Q2 · MEDICINE

Article

Author: Xu, Wenhao ; Sun, Chen ; Yu, Jingbo ; Zhu, Xingyi ; Zheng, Lei ; Dushkin, Alexandr V ; Su, Weike ; Zhang, Qihong

Inositol hexanicotinate (IHN) self-micelle solid dispersion (SD) with glycyrrhizic acid (GA) and arabic gum (AG) was prepared by mechanical ball milling process to improve the solubility, stability of amorphous state, and bioavailability of IHN, which enhanced the treatment of IHN on hyperlipidemia and nonalcoholic fatty liver disease (NAFLD). The physicochemical properties of IHN/GA/AG SDs in solid state were characterized by differential scanning calorimetry, X-ray diffraction studies, and scanning electron microscopy. The characteristics of the sample solutions were analyzed by reverse-phase HPLC, particle characterization, critical micelle concentration, and transmission electron microscopy. Further pharmacokinetic study of this SD formulation in rats showed a significant 3.3-fold increase in bioavailability compared to pure IHN. Moreover, biomarkers in serum and liver of NAFLD mice were significantly ameliorated after oral administration of IHN/GA/AG SDs for 15 days. Altogether, these results establish the mechanochemically prepared IHN/GA/AG SDs as an efficacious formulation for the treatment of hyperlipidemia and NAFLD.

100 Deals associated with Inositol Nicotinate

External Link

KEGG	Wiki	ATC	Drug Bank
D01813	Inositol Nicotinate	C04AC03	DB08949

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperlipidemias	-	-	-
Peripheral Vascular Diseases	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis